Jichi medical university, Private university in Shimotsuke, Japan

Tokyo, April 19 Japan's Health Ministry on Tuesday approved the use of a Covid-19 vaccine developed by US pharmaceutical company Novavax to be used on people aged 18 and above.The Novavax vaccine will mark the fourth Covid inoculation approved in Japan, although will be the first protein-based vaccine compared to those developed by Pfizer and Moderna that are messenger RNA-based (mRNA) jabs, Xinhua news agency reported.The ministry hopes the Novavax jab can be administered to those who are likely to show allergic reactions to mRNA vaccines so they can still be vaccinated against the virus which is yet to be brought under control in Japan.According to Japan's public broadcaster NHK, protein-based vaccines are known to cause relatively fewer reactions, with the thinking being among the ministry that this will help the uptake of those who are as yet unvaccinated because they have been worried about side effects.The Novavax vaccine requires recipients to be jabbed twice with a three-week period between doses, the ministry said, although a third booster shot will be allowed six months or more after the second jab.Takeda Pharmaceutical will manufacture the jab locally and distribute the Novavax vaccine and is under contract to supply 150 million doses of the vaccine to the government within a year, according to official accounts.The rollout, they said, is expected to begin in late May, with Health Minister Shigeyuki Goto saying on Tuesday that the government purchased the vaccine last September to make sure Japan was in possession of a stable supply should restrictions be applied on overseas vaccines.Goto also said Novavax as a vaccine also got the green light from the government specifically because it is protein-based and is regarded as safe and effective.He added that the Japanese government had always intended to procure a variety of different vaccines so as to offer the public more choices.Local governments have been asked by the health ministry to open at least one site where the Novavax vaccine can be administered to make sure that those who prefer the protein-based jab, or require a non-mRNA for whatever reason, have access to it.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Jichi Medical UniversityFOLLOW

Jichi medical university, Latest News

E-NEXCO INDIA Pvt Ltd (ENI), has launched road network survey business utilizing owned specific vehicle, namely E-NEXCO Eye for the Indian markets to measure road surface conditions safely, quickly and accurately. ...

New Delhi, April 24 The tablet market in the Asia-Pacific region will reach 57.2 million units in 2022, ... ...

The Japanese coast guard has rescued 10 people from a tourist boat that went missing off Japan's Hokkaido Island, the Japanese media reported on Sunday. ...

Seven people from the Japanese tour boat that went missing with 26 people on board have been found, after ... ...

In the era of carbon neutrality, Idemitsu Kosan is trying to develop new industrial material. The company has rich experience in the chemical advanced fiber material field. ...

Tokyo, April 22 More than 100 Japanese lawmakers visited the war-linked Yasukuni Shrine in Tokyo on Friday on ... ...

Orchestra is a New Japanese Technology for effective Rice BPH management with excellent safety to beneficial insects. ...

Tokyo, April 19 Japan's Health Ministry on Tuesday approved the use of a Covid-19 vaccine developed by US ... ...